Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

December 12, 2025

Toxicological Sciences: Developmental Toxicology Profile of the IRAK4 Degrader KT-474

Enerson, et al.
Read More
October 27, 2025

Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models

American College of Rheumatology (ACR) 2025
Read More
October 27, 2025

Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in Rodent Models of Rheumatoid Arthritis

American College of Rheumatology (ACR) 2025
Read More
September 29, 2025

Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults

European Respiratory Society (ERS) 2025 Congress – Late Breaking Presentation
Healthy Volunteers
Read More
September 17, 2025

KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects

European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
Healthy Volunteers
Read More
September 17, 2025

The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models

European Academy of Dermatology & Venereology (EADV) 2025
Asthma Atopic Dermatitis (AD)
Read More
May 19, 2025

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically

American Thoracic Society (ATS) 2025
Read More
May 17, 2025

Revolutionizing Immunology: Oral Medicines with Biologics-like Activity

American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
Read More
March 8, 2025

Clinical and Translational Science: Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults

Agarwal, et al.
Read More
October 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

American College of Allergy, Asthma & Immunology (ACAAI) 2024
Read More